Currently Viewing:
European Society of Cardiology (ESC) 2017
Dr Christi Deaton on the Most Important Steps for Cardiovascular Prevention
November 12, 2017
Dr John Rumsfeld: We're Just at the Beginning of the Digital Health Transformation
November 09, 2017
Dr Jeanette Stingone on Environmental Factors That Impact Public Health
November 07, 2017
Christi Deaton: Challenges of Motivating Patients to Participate in CVD Prevention Strategies
November 04, 2017
Dr John Rumsfeld on the Digital Transformation of Cardiovascular Medicine
October 24, 2017
Dr Deepak Bhatt on the Impact of the COMPASS Trial on Standard of Care
October 19, 2017
Dr Jeanette Stingone: Air Pollution Is an Issue Everywhere in the US
October 12, 2017
Dr John Rumsfeld Outlines ACC's Main Goals for the Future of Cardiology
October 07, 2017
Dr Simon Gibbs Discusses the Future of Pulmonary Hypertension Treatments
October 03, 2017
Currently Reading
Dr Steven Nissen Argues for Aggressively Lowering LDL Cholesterol
October 01, 2017
Dr John Eikelboom on the Surprising Results of the COMPASS Trial
September 15, 2017
Dr Simon Gibbs Outlines Monotherapy vs Combination Therapy in Pulmonary Hypertension
September 14, 2017
Dr Christi Deaton: Ask Cardiac Patients About Their Diet and Exercise
September 12, 2017
Dr Steven Nissen on Which Patients Should Be Treated With PCSK9 Inhibitors
September 11, 2017
Dr Jeanette Stingone on Lasting Cardiovascular Effects of Prenatal Exposure to Air Pollution
September 07, 2017
Dr Christi Deaton on Promoting Better Self-Management for Patients With CVD
August 29, 2017
Dr John Eikelboom: COMPASS' Rivaroxaban Plus Aspirin Will Become Standard for CAD, PAD
August 29, 2017
Comorbidities in Patients With Heart Failure: Treating the Whole Patient
August 29, 2017
Dr Simon Gibbs on Daily Management of Patients With Pulmonary Hypertension
August 28, 2017

Dr Steven Nissen Argues for Aggressively Lowering LDL Cholesterol

There is an ongoing debate about how aggressively to lower low-density lipoprotein (LDL) cholesterol, but Steve Nissen, MD, of Cleveland Clinic, argues that studies have shown an aggressive approach to lowering LDL always shows benefits.


There is an ongoing debate about how aggressively to lower low-density lipoprotein (LDL) cholesterol, but Steven Nissen, MD, of Cleveland Clinic, argues that studies have shown an aggressive approach to lowering LDL always shows benefits.

Transcript (slightly modified)

What is the argument for aggressively lowering low-density lipoprotein cholesterol?

We’ve been studying LDL now for 30 years. There are studies involving hundreds of thousands of patients, large randomized controlled trials, and the one thing that’s been constant is whenever we’ve driven LDL to lower levels, we have seen benefits in an adequately designed, adequately sized trial. This goes back even before statins—we had that kind of data. In fact, recently we have seen benefits of lowering LDL to as low as 30 milligrams per deciliter. So, I think it’s a compelling case that lower LDL equals less cardiovascular events.

Are there concerns with aggressively lowering LDL cholesterol for patients who might not be good candidates?

It turns out that the evidence looks pretty much across the board. Now, it all depends on the drugs you are going to use.  We know that higher dose statins have a somewhat higher risk of adverse effects than low dose statins, but these are very safe drugs. Similarly, adding ezetimibe is another very safe drug, PCSK9 inhibitors—very safe. We have pretty good data from multiple trials, including some that we have run, that show that there are no real safety issues with low LDLs. There may be drug specific safety issues, but we used to say you can’t be too rich or too thin, we now say you can’t be too rich, too thin, or have too low an LDL.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!